Alloy Therapeutics, Inc.’s Post

4/17 Webinar: How to take back control of your #ITHelpdesk from #Slack DMs. Cohere, Xilio Therapeutics, Foqal share experience. Register here: https://hubs.ly/Q02pyRpN0

By signing up to the Argenica Therapeutics Investor Hub, you are able to stay up to date with what's going on within the business. Whether you're a shareholder, investor or someone who's interested in the development of ARG-007, receive the most up-to-date information direct to your inbox. Stay up to date with Argenica Therapeutics ➡ https://bit.ly/3UO305v #ASX #AGN #investorrelations #strokeawareness #investornews #ARG007

BCVG notes increased investment activity within the regenerative bone healing segment, with the recent formation of TherageniX, strategic investment in Renovos Biologics Limited and the NASDAQ listing of Carmell Therapeutics.  To learn more about our perspectives and approach to building value in regenerative medicine, please schedule a meeting with our team:  https://lnkd.in/em7xgH8i #Bruder Consulting, #RegenerativeMedicine, #Orthobiologics

PROTACs have the potential to produce groundbreaking drugs, but they face challenges with DMPK profile. Luckily, the SAR data of linkers presented here may offer a solution for some of the difficulties associated with PROTACs. Check out the linkers' SAR data to learn more about how they can help advance drug development. #PROTACs #drugdevelopment #SARdata #DMPKprofile

❗❗❗📚💡 C4 Therapeutics, Inc. patent for a #SMARCA2 degraded Numerous interesting chemistry and extensive pharmacokinetic data for SAR analysis💡 New bicyclic binders for CRBN, including those featured in the recent CRBN bicyclic binder, are also included - https://lnkd.in/dckGRu_9 link to patent - https://lnkd.in/dNtga75s #TPD #Targeted_Protein_Degradation #protac #CRBN #SMARCA2

The trial is a substudy of an ongoing, first-in-human trial evaluating the safety of CT-0508 (Carisma Therapeutics) alone in patients with #solidtumors. #celltherapy #solidtumor Merck Read more: https://ow.ly/QM3U50PCxv5

The way to win at healthcare investing is knowing the best companies BEFORE they are public. Thanks, LifeSci, for blazing the trail.

Pruritus Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030) https://lnkd.in/eVPdMPkT #marketanalysis #marketresearch #marketresearchreports #businessintelligence

Check this out! As a scientist, patent attorney and entrepreneur, I believe that innovation is the genesis of therapeutics that changes patients lives. Get informed and support strong patent rights to protect these innovations and the businesses that they help build!

AsclepiX Therapeutics, Inc. has announced that it has secured a $10 million Series A-3 financing. The round was led by Perceptive Advisors with participation from the existing investors Hibiscus Capital Management Fund II and Rapha Capital Management, LLC and its managed fund, Rapha Capital Management, LLC PE Life Sciences Fund VI, in addition to a new outside investor. The lead clinical candidate, integrin regulating peptide AXT107 (gersizangitide), has a novel mechanism of action that inhibits neovascularization, reduces vascular permeability, and suppresses vascular inflammation. In a microparticulate suspension, AXT107 may be capable of maintaining sustained biological activity with one injection well beyond current standard of care. https://bit.ly/3rH7VZw